Loader

Pathways

PathWhiz ID Pathway Meta Data

PW132554

Pw132554 View Pathway
metabolic

Zeaxanthin Drug Metabolism

Homo sapiens
Zeaxanthin is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zeaxanthin passes through the liver and is then excreted from the body mainly through the kidney.

PW012895

Pw012895 View Pathway
metabolic

Zeaxanthin Biosynthesis

Arabidopsis thaliana
Zeaxanthin biosynthesis is a pathway that occurs in the chloroplast by which lycopene becomes zeaxanthin, one of the most common carotenoid alcohols found in nature . The first two reactions are catalyzed by lycopene beta cyclase which uses NAD(P)H as a cofactor to convert lycopene into gamma-carotene and gamma-carotene into beta-carotene. The last two reactions are catalyzed by beta-carotene 3-hydroxylase which uses ferredoxin and Fe2+ as cofactors to convert beta-carotene into beta-cryptoxanthin and beta-cryptoxanthin into zeaxanthin.

PW124096

Pw124096 View Pathway
metabolic

Zeatin Biosynthesis

Arabidopsis thaliana
Zeatin encourages lateral bud growth, resulting in bushier plants. It stimulates cell division when sprayed on meristems. Terpenoid backbone biosynthesis produces dimethylallyl diphosphate which, with different reactants, can result in different products with a byproduct of diphosphate. When reacted with tRNA adenine via tRNA dimethylallyltransferase, it results in the formation of tRNA containing 6-isopentenyl adenosine. When reacted via adenylate isopentenyltransferase 1, chloroplastic with either ATP, ADP, or AMP, it results in the formation of the corresponding isopentenyl, which in turn reacts with oxygen and reduced NADPH hemoprotein reductase via cytokinin hydroxylase, resulting in the formation of trans-zeatin riboside with the corresponding phosphates and byproducts of water and oxidized NADPH hemoprotein reductase.

PW146905

Pw146905 View Pathway
drug action

Zanubrutinib Drug Metabolism Action Pathway

Homo sapiens

PW132540

Pw132540 View Pathway
metabolic

Zanubrutinib Drug Metabolism

Homo sapiens
Zanubrutinib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zanubrutinib passes through the liver and is then excreted from the body mainly through the kidney.

PW144675

Pw144675 View Pathway
drug action

Zanamivir Drug Metabolism Action Pathway

Homo sapiens

PW127615

Pw127615 View Pathway
drug action

Zanamivir Action Pathway

Homo sapiens
Zanamivir, also known as Relenza, is an inhibitor of the viral neuraminidase protein. This antiviral is used to treat and prevent influenza A and B infections. By interacting with the neuraminidase, Zabamivir renders the influenza virus unable to escape its host cell. Neuraminidases are essential for the cleaving of the terminal sialic acids on the glycosylated HA during the virus budding to facilitate its release. In consequence, the virus will not be able to infect other cells. This molecule is available as an intravenous solution or as a powder for inhalation.

PW145060

Pw145060 View Pathway
drug action

Zaleplon Drug Metabolism Action Pathway

Homo sapiens

PW128435

Pw128435 View Pathway
drug action

Zaleplon Action Pathway

Homo sapiens
Zaleplon, a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class, serves as a sedative used for the short-term treatment of insomnia in adults. Functioning within the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex, it shares certain pharmacological attributes with benzodiazepines despite its distinct chemical structure. Classified as a schedule IV drug in the United States, Zaleplon interacts with the CNS GABAA-receptor chloride ionophore complex at benzodiazepine (BZ) omega-1 (BZ1, ο1) receptors. Its mechanism of action involves subunit modulation of the GABABZ receptor chloride channel macromolecular complex, and it also selectively binds to the brain omega-1 receptor found on the alpha subunit of the GABA-A/chloride ion channel receptor complex, enhancing t-butyl-bicyclophosphorothionate (TBPS) binding. Zaleplon, distinctly separate from benzodiazepines and other hypnotic agents, effectively addresses short-term insomnia by interacting with these receptor systems.

PW176308

Pw176308 View Pathway
metabolic

Zalcitabine Predicted Metabolism Pathway

Homo sapiens
Metabolites of Zalcitabine are predicted with biotransformer.